News

April 24, 2024

Cellphire Therapeutics is nominated for Emerging Life Science Company of the Year by Maryland Tech Council!

The nomination underscores Cellphire's commitment to innovation and its contributions to the life sciences industry. With a focus on developing next-generation allogeneic cellular therapeutic technologies, Cellphire has emerged as a leader in the field, driving advancements that have the potential to revolutionize product availability.

April 23, 2024

Cellphire Therapeutics Issued New Core Technology Patent For Use of Stabilized Platelet Loaded With Anti-Cancer Agents

Cellphire Therapeutics was issued a patent, entitled Platelets Loaded with Anti-Cancer Agents (US Patent 11,965,178 B2 ('178 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) and/or FPH technology loaded with anti-cancer compounds for treating several cancers efficaciously while reducing toxicity.

September 26, 2023

Cellphire Therapeutics Issued New Core Technology Patent covering the use of Stabilized Platelets for Drug Delivery

Cellphire Therapeutics, Inc. was issued a patent entitled "Platelets as Delivery Agents" (US Patent 11,767,511, B2 ('511 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) for select drug delivery applications.

September 12, 2023

Cellphire Therapeutics Issued New Core Technology Patent Covering Novel Manufacturing Processes and Product Attributes

Cellphire is excited to announce that the United States Patent and Trademark Office (USPTO) issued a patent, entitled "Materials and Methods for Producing Blood Products" (US Patent 11,752,468 B2 ('468 Patent) covering the technology used to produce Freeze-dried Platelet-derived Hemostat (FPH).

July 18, 2023

Cellphire Therapeutics Issued New Core Technology Patent covering FPH technology as an Antiplatelet Reversal Agent

Cellphire Therapeutics, Inc. was issued a patent entitled "Thrombosomes as an Antiplatelet Reversal Agent" (Patent US 11,701,388 B2 ('388 Patent)) covering the application of our Freeze-Dried Platelet-Derived Hemostat Technology (FPH) to restore hemostasis on patients bleeding as a result of all classes of antiplatelet antagonists.

April 18, 2023

First patient treated in Phase 2 clinical trial of Thrombosomes® in Acute Thoracic Aortic Dissections (TTAD)

Cellphire Therapeutics announced today the enrollment and treatment of the first patient in an investigator-initiated clinical trial in Denmark.

March 7, 2023

Cellphire Therapeutics Conducted CPP Investigator Meeting

Cellphire Therapeutics conducted first in-person investigator meeting in San Diego focused on our Cryopreserved Platelet Product.

February 13, 2023

Cellphire Therapeutics Published in Journal of Cardiothoracic and Vascular Anesthesia

Cellphire Therapeutics is proud to announce the publication of “In Vitro Treatment of Extracorporeal Membrane Oxygenation (ECMO) Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets” in the Journal of Cardiothoracic and Vascular Anesthesia.